



3Q FY2009

(Fiscal Year Ending March 31, 2010)

Financial Results Presentation

February 2, 2010



Safe Harbor Statement

- Materials and information provided during this presentation may contain so-called “forward-looking statements.” These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.
- Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors; challenges inherent in new product development, including completion of clinical trials; claims and concerns about product safety and efficacy; obtaining regulatory approvals; domestic and foreign healthcare reforms; trends toward managed care and healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations.
- Also, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and failure to gain market acceptance.
- The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.



	Apr. - Dec. 2008		Apr. - Dec. 2009	
	Results		Results	%
	598.7		604.5	100.0
	118.9		121.5	20.1
	479.8		482.9	79.9
	116.9		116.8	19.3
	289.5		281.1	46.5
	73.4		85.1	14.1
Ordinary Income	66.4	11.1	80.1	13.2
	39.2			8.9

Sales of Major Products

Products	Area	Apr. - Dec. 2008		Apr. - Dec. 2009	
			%		%
			38		39
	Japan	35.0		43.0	123
	U.S.	76.5		61.3	80
	[\$ Million]	[744]		[655]	[88]
	Europe	7.5		6.2	83
	Asia		21		
Oncology - related products	Total	58.8	10	57.8	98 [108]

Operating Income by Geographic Area

(Billion Yen, %)

	Apr. - Dec. 2008		Apr. - Dec. 2009		
	Results	%	Results	%	YOY
Japan	60.9	80.9	75.8	85.3	124
North America	6.9	9.1	5.8	6.5	84
Europe	2.7	3.6	3.9	4.4	145
China	1.7	2.3	1.5	1.7	88
AOME	3.1	4.1	1.9	2.1	60
Overseas Total	14.4	19.1	13.0	14.7	90
Elimination/ Corporate	(1.9)		(3.8)		
Total	73.4		85.1		116



Four products targeted for launch in FY2010 are making steady progress

Aricept-SR

- New sustained-release technology with stable, favorable PK profile that maintains higher anti-cholinesterase activity to seek better benefits for patients
- Aricept SR could potentially provide additional benefit to moderate to severe Alzheimer's disease (AD) patients who are already prescribed Aricept 10mg mono-therapy or in combination with memantine
- Out of approx. 5.3 million AD patients in the U.S., approximately 65% (approx. 3.4 million) of them are estimated to be moderate to severe AD patients according to company assumption
- Aiming to meet the unmet medical needs where no further improvement is expected with current treatments

Eribulin (E7389)

Aiming to establish the new gold standard for breast cancer

- Anticancer agent/Microtubule dynamics inhibitor
(novel mechanism of action on microtubule)
- Phase III in breast cancer (study 305: third line): eribulin showed statistically significant extension in the primary endpoint of median survival, compared to physician's choice group
- Study 221 in Japan for breast cancer: response rate (complete response + partial response) of 21.3% (17/80)
- Completed patient enrollment for phase III in breast cancer (study 301: second line)
- Phase II trial in sarcoma and phase Ib/II in non-small cell lung cancer (combination with carboplatin) ongoing

Targeting NDA/MAA submissions in Japan, U.S. and Europe: March 2010

Incidence of breast cancer: more than 1 million annually (worldwide: internal estimates)

Eritoran (E5564)

First-in-class TLR4 antagonist for severe sepsis treatment
Aiming to be a truly life-saving drug

- Sepsis treatment/TLR4 antagonist (novel mechanism of action)
- Eritoran could potentially save 100 lives every single day in the U.S. alone*
- Achieved 1500th patient enrollment for study 301 on December 9, 2009
- Achieved patient-out for 1500th patient on January 6, 2010
- DMC (Data Monitoring Committee) scheduled for late March

* Source: Tidswell et al, Crit Care Med (in press)

Targeting NDA/MAA submissions in Japan, U.S. and Europe: 1Q FY2010

Number of severe sepsis patients: approximately 0.79 million (Japan, U.S. and Europe: internal estimate)

AcipHex-ER

Seeking the potentially strongest PPI maintaining the longest pH holding time

- Goal is to meet the unmet medical needs of patients suffering from GERD and heartburn
 - Approximately 1/3 of all GERD sufferers take both an H2 antagonist and PPI to cope with their symptoms
 - Nocturnal heartburn is still unresolved problem
- Through its long-acting formulation, showed its longer pH holding time versus esomeprazole (phase I: study 017)
- Achieved the database lock for six phase III trials; required criteria for NDA submission have been met

Targeting NDA submission in U.S.: March 2010

Number of GERD patients: approximatel



Japan and China to lead Eisai's growth




- Significant qualitative improvement in provision of medical information with enhanced market satisfaction by integration of four businesses (prescription drugs, OTC, diagnostics, and generics)
- With high growth of major products, the prescription drugs business growth (+13%) outperformed the market by 5 points^{*1}

*1: Copyright 2010 IMS Health. All rights reserved. Source: Japan JPM Apr. - Dec. 2008, Apr. - Dec. 2009. Printed with permission.

*2: Internal estimates

*3: Copyright 2010 IMS Health. All rights reserved. Source: Japan JPM Apr. 2008 - Mar. 2009, Oct. - Dec. 2009. Printed with permission.



*1: Submission by SymBio Pharmaceuticals Limited *3: Submission by

No.1 in China among Japanese peers for the past 12 months as a result of high growth that outperformed the market

+44% YOY (Apr. - Dec., 2009; local currency basis)

- Aricept: +45% (local currency basis)
- Pariet: +67% (local currency basis)

Accelerating growth by leveraging new listing of four products on the National Reimbursement Drug List

- Aricept, Selbex, alpha-Lipon 300 STADA, and Kestine
- Methycobal: prescription restriction of “severe complications of diabetes” has been lifted; realizing expanded access to all patients with peripheral neuropathy
- Listed products such as Pariet remained on the list

Expansion of franchise in response to local disease structure in China

(Disease structure in the emerging areas to shift from communicable to non-communicable diseases)

- Hepatic disease area (Hepatitis B: approx. 90 mil.; Hepatitis C: approx. 40 mil.)*

Stronger Neo-Minophagen C, Glycyron, clevudine, LIVACT, E5501 (AKR-501)

- Diabetes area (approx. 40 mil.)

Methycobal, alpha-Lipon 300 STADA, Glufast

- Oncology area (breast cancer: approx.



E5501 (AKR-501)

Aiming for best-in-class that meets global unmet medical needs

- Treatment for thrombocytopenia/thrombopoietin receptor agonist
- Completed the acquisition of AkaRx, Inc. in the U.S. and obtained the exclusive worldwide rights to develop, market, and manufacture E5501 (AKR-501)
- Confirmed POC in Phase II trial for idiopathic thrombocytopenic purpura (ITP)

64 ITP patients: 28-day oral dosing - effective response rate of platelet increase

Visit	Placebo	E5501			
		2.5 mg	5 mg	10 mg	20 mg
Day 14	0%	20%	60%	78.6%**	93.3%**
Day 28	0%	13.3%	53.3%	50%	80.0%**

Confirmed statistically significant response rate of platelet increase

** p<0.005 vs placebo

- Striving to develop for indications associated with hepatic diseases to address high unmet medical needs in emerging areas
 - 7% of population is infected by hepatitis B and 3% of population is infected by hepatitis C
 - Antiviral agent market in China: 1,984 million RMB (approx. 26 billion yen based on 1 RMB = 13 yen) in FY2008; expansion by average CAGR of 34% for the past five years
- Phase II trials ongoing for thrombocytopenia associated with hepatic diseases [viral hepatitis, alcoholic hepatitis, and NASH (non-alcoholic steatohepatitis)]
- Planning for phase II trial for improvement of platelet decrease in viral hepatitis patients who require interferon therapy

FY2009 Financial Forecast

(Billion Yen, %)

	FY2008		FY2009		
	Results	%	Forecast	%	YOY
Net Sales	781.7	100.0	803.0	100.0	103
Cost of Sales	152.5	19.5	161.0	20.0	106
Gross Profits	629.3	80.5	642.0	80.0	102
R&D Expenses	156.1	20.0	181.0	22.5	116
SG&A Expenses	381.4	48.8	379.5	47.3	100
Operating Income	91.8	11.7	81.5	10.1	89
Ordinary Income	82.6	10.6	74.5	9.3	90
Net Income	47.7	6.1	40.3	5.0	85
Cash Income	119.0		120.5		
Dividend per Share (yen)	140		150		

GAAP basis